Skip to main content

Tags

Seneste nyheder

YESCARTA® (AXICABTAGENE CILOLEUCEL) RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY DLBCL AND MBCL, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY

YESCARTA® (AXICABTAGENE CILOLEUCEL) RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY DLBCL AND MBCL, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY

Pressemeddelelser   •   Aug 27, 2018 15:16 CEST

Gilead today announced that the European Commission (EC) has granted Marketing Authorization for Yescarta® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

EUROPEAN  COMMISSION  GRANTS  MARKETING  AUTHORIZATION  FOR  GILEAD’S  EPCLUSA® ▼(SOFOSBUVIR/VELPATASVIR)  FOR  THE TREATMENT  OF  ALL  GENOTYPES  OF  CHRONIC  HEPATITIS  C

EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR GILEAD’S EPCLUSA® ▼(SOFOSBUVIR/VELPATASVIR) FOR THE TREATMENT OF ALL GENOTYPES OF CHRONIC HEPATITIS C

Pressemeddelelser   •   Jul 11, 2016 08:32 CEST

The European Commission has granted marketing authorization for Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg), the first pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

GILEAD PRESENTS  FOLLOW-UP  DATA  FROM  IDELALISIB  (ZYDELIG®)   REGISTRATIONAL  STUDIES  IN  PATIENTS  WITH  CHRONIC  LYMPHOCYTIC  LEUKEMIA,  FOLLICULAR  LYMPHOMA  AND  SMALL  LYMPHOCYTIC  LYMPHOMA

GILEAD PRESENTS FOLLOW-UP DATA FROM IDELALISIB (ZYDELIG®) REGISTRATIONAL STUDIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA, FOLLICULAR LYMPHOMA AND SMALL LYMPHOCYTIC LYMPHOMA

Pressemeddelelser   •   Dec 13, 2014 15:17 CET

-- Results Describing Long-Term Safety and Disease Control Presented at the 56th American Society of Hematology Annual Meeting --

Europa-kommissionen giver markedsføringstilladelse til Gileads Harvoni til behandling af kronisk hepatitis C-infektion

Europa-kommissionen giver markedsføringstilladelse til Gileads Harvoni til behandling af kronisk hepatitis C-infektion

Pressemeddelelser   •   Nov 19, 2014 08:42 CET

EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR GILEAD’S HARVONI®▼ (LEDIPASVIR/SOFOSBUVIR), THE FIRST SINGLE TABLET REGIMEN TO TREAT THE MAJORITY OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 AND 4.

 DET EUROPÆISKE UDVALG FOR HUMANMEDICINSKE LÆGEMIDLER, CHMP, VEDTAGER POSITIV UDTALELSE FOR GILEADS HARVONI ® ▼ (LEDIPASVIR/SOFOSBUVIR) TIL BEHANDLING AF KRONISK HEPATITIS C-INFEKTION HOS VOKSNE

DET EUROPÆISKE UDVALG FOR HUMANMEDICINSKE LÆGEMIDLER, CHMP, VEDTAGER POSITIV UDTALELSE FOR GILEADS HARVONI ® ▼ (LEDIPASVIR/SOFOSBUVIR) TIL BEHANDLING AF KRONISK HEPATITIS C-INFEKTION HOS VOKSNE

Pressemeddelelser   •   Sep 26, 2014 15:54 CEST

Gilead Sciences, Inc. (Nasdaq: GILD) har i dag meddelt, at Udvalget for Humanmedicinske Lægemidler (CHMP), den videnskabelige komité under det Europæiske Lægemiddelagentur (EMA), har afgivet en positiv udtalelse om virksomhedens ansøgning om markedsføringstilladelse for Harvoni®, der er under udvikling.

European Commission Grants Marketing Authorization for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

European Commission Grants Marketing Authorization for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

Pressemeddelelser   •   Sep 26, 2014 08:42 CEST

The European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers – chronic lymphocytic leukemia and follicular lymphoma. "Zydelig is a welcomed treatment option that offers a new approach in the management of these cancers," said Professor Peter Hillmen, Leeds Teaching Hospitals NHS Trust.

EUROPA-KOMMISSIONEN GIVER MARKEDSFØRINGSTILLADELSE TIL GILEADS SOVALDI® (SOFOSBUVIR) TIL BEHANDLING AF KRONISK HEPATITIS C-INFEKTION

EUROPÆISK CHMP GIVER POSITIV UDTALELSE OM GILEAD SCIENCES’ SOVALDI®- TIL BEHANDLING AF KRONISK HEPATITIS C-INFEKTION

Pressemeddelelser   •   Nov 22, 2013 19:03 CET

Foster City, CA, 22. November, 2013 – Gilead Sciences, Inc. (Nasdaq: GILD) har i dag meddelt, at Udvalget for Lægemidler til mennesker (CHMP), den videnskabelige komité under det Europæiske Lægemiddelagentur (EMA), har givet en positiv udtalelse til virksomhedens ansøgning om markedsføringstilladelse for Sovaldi®- (sofosbuvir, 400 mg tabletter)